Search company, investor...

Compare Active Pass Pharmaceuticals vs InterveXion Therapeutics

Customers evaluate the quality of Active Pass Pharmaceuticals's products using the following success metrics.

Overview

Active Pass Pharmaceuticals is based in Canada

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

InterveXion Therapeutics is 22 yrs old and is based in United States.

InterveXion Therapeutics is a drug discovery and development company focused on antibody-based therapies for treating human disease. The company are developing monoclonal antibodies to treat substance abuse from PCP and methamphetamine.

Demo Video

Demo not available because Active Pass Pharmaceuticals has not claimed their profile.

Work for Active Pass Pharmaceuticals? Show off your product.

Demo not available because InterveXion Therapeutics has not claimed their profile.

Work for InterveXion Therapeutics? Show off your product.

Leadership

David MacDonald (Chief Executive Officer, President)

Keith W. Ward (Chief Executive Officer, President)

See all 4 people

Funding

InterveXion Therapeutics last raised $13.8M on 11/1/2021.

Investors

National Institutes of Health and BioVentures

Product

Benefits

Products

Customers

Known Partners

Why They Buy

Information not available because Active Pass Pharmaceuticals has not claimed their profile.

Work for Active Pass Pharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for Active Pass Pharmaceuticals?

Claim your profile now.

Information not available because InterveXion Therapeutics has not claimed their profile.

Work for InterveXion Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can

Show your primary competitive advantage
Highlight your competitive differentiation
Show why customers evalute your products
Explain why customers choose your products and services

Work for InterveXion Therapeutics?

Claim your profile now.